Taiwan Semi Puts Up Strong First Quarter, Gives Cautious Outlook
April 18, 2024
Image: Taiwan Semiconductor’s shares have rallied considerably since the October 2022 bottom. By Brian Nelson, CFA On April 18, Taiwan Semiconductor (TSM) reported better than expected first-quarter 2024 results. On a year-over-year basis, revenue advanced 16.5%, while both net income and diluted earnings per share increased 8.9%. On a U.S. dollar basis, first-quarter revenue increased 12.9% on a year-over-year basis. Taiwan Semi’s gross margin for the quarter came in at 53.1%, its operating margin was 42.0%, while its net profit margin was 38.0%. During the first quarter, the company noted that shipments of 3-nanometer accounted for 9% of total wafer revenue, while shipments of 5-nanometer and 7-nanometer accounted for 37% and 19%, respectively in the quarter. Management noted that advanced
ASML Reports First Quarter Results, Reiterates Guidance
April 17, 2024
Image: ASML Holding is one of our favorite semiconductor ideas. By Brian Nelson, CFA On April 17, ASML Holding (ASML) reported decent first quarter 2024 results. First quarter net sales came in at €5.29 billion on a gross margin of 51.0%. Net income was €1.22 billion in the quarter. Net bookings in the first quarter of 2024 came in at €3.6 billion, down sequentially from the strong net bookings number delivered in the fourth quarter of 2023. The company continues to be shareholder friendly, paying dividends and buying back €400 million worth of stock during the first quarter. Management had the following to say about the quarterly results and outlook: Our first-quarter total net sales came in at €5.3 billion,
Johnson & Johnson Narrows 2024 Outlook, Raises Dividend
April 16, 2024
Image Source: J&J By Brian Nelson, CFA Johnson & Johnson (JNJ) reported mixed first-quarter 2024 results on April 16 with adjusted operational growth of 4%. Excluding its COVID-19 vaccine sales, revenue growth was 7.7% in the period. First quarter adjusted earnings per share advanced 12.4%, to $2.71, which was slightly better than the consensus forecast. Management was upbeat in the press release: Johnson & Johnson’s solid first quarter performance reflects our sharpened focus and the progress in our portfolio and pipeline. Our impact across the full spectrum of healthcare is unique in our industry, and the milestones achieved this quarter reinforce our position as an innovation powerhouse. J&J’s adjusted operational sales for its Innovative Medicine division increased 2.5%, while adjusted operational sales
UnitedHealth Group Reiterates 2024 Adjusted Net Earnings Outlook
April 16, 2024
Image: UnitedHealth Group’s shares have been choppy during the past couple years. By Brian Nelson, CFA On April 16, UnitedHealth Group (UNH) reported better-than-expected first quarter 2024 results. Revenue advanced nearly $8 billion on a year-over-year basis, to $99.8 billion, while adjusted earnings per share came in at $6.91. The company’s results were quite messy given the impact of the recent cyberattack on its business as well as the sale of its Brazil operations. UnitedHealth Group noted that the cyberattack impact in the first quarter was $0.74 per share, and the firm expects the full year 2024 impact to be $1.15-$1.35 per share. The company also recorded a largely non-cash $7 billion charge in the quarter due to the sale
Goldman Sachs Delivers in First Quarter
April 15, 2024
Image Source: Goldman Sachs By Brian Nelson, CFA On April 15, Goldman Sachs (GS) reported better-than-expected first quarter 2024 results that showed a nice beat on both the top and bottom lines. Net revenue came in at $14.21 billion (consensus was at $12.9 billion) for the first quarter of 2024, roughly 16% higher than the mark achieved in the first quarter of last year. Goldman Sachs experienced higher net revenues across all of its segments. On an annualized basis, its annualized ROE came in at 14.8% in the quarter and its annualized ROTE came in at 15.9%. Goldman Sachs’ diluted earnings per common share was $11.58 (consensus was $8.68 per share) during the first quarter of the year compared with
Vertex Pharma to Acquire Alpine Immune Services
April 13, 2024
Image: Vertex Pharma’s shares have had a nice run the past couple years. By Brian Nelson, CFA On April 10, Vertex Pharma (VRTX) announced that it had entered into an agreement where Vertex will acquire Alpine Immune Services (ALPN) for $65 per share or ~$4.9 billion in cash. Alpine’s focus is on developing protein-based immunotherapies, and the company’s lead product, povetacicept, holds great promise in patients with IgA nephropathy, a life-threatening chronic kidney disease. Here’s what Vertex management had to say about the proposed transaction: Alpine is a compelling strategic fit for Vertex and furthers our ambition of using scientific innovation to create transformative medicines targeting serious diseases with high unmet need in specialty markets. We look forward to welcoming
JPMorgan Cautious on Geopolitical Tensions and Inflationary Pressures
April 12, 2024
Image Source: Hakan Dahlstrom By Brian Nelson, CFA On April 12, JPMorgan (JPM) reported mixed first-quarter 2024 results. The company reported revenue of $41.9 billion and adjusted net income of $14 billion, or $4.63 per share, which compared to the consensus forecast of $4.13 at the time. For the first quarter, JPMorgan registered a ROE of 17% and a ROTCE of 21%. Credit costs totaled $1.9 billion and included $2.0 billion of net charge-offs and a $72 million net reserve release. Average loans were up 16%, including First Republic, while average deposits were up 2%, including First Republic. It ended the quarter with a CET1 capital ratio of 15.0% and tangible book value per share of $88.43, implying a price-to-tangible
Fastenal Puts Up Mixed First Quarter Results
April 11, 2024
Image: Fastenal reported mixed first quarter 2024 results. We like its business model quite a bit. By Brian Nelson, CFA On April 11, Fastenal Company (FAST) reported mixed first-quarter fiscal 2024 results with revenue and earnings per share coming in slightly lower than expectations. Net sales advanced 1.9% for the three-month period ending March 31. The company noted that adverse weather impacted sales in its first quarter by about 10 to 30 basis points on a net basis. Operating income nudged lower in the quarter modestly, while net income advanced 0.9% in the period on a year-over-year basis. Diluted earnings per share was roughly flat in the quarter on a year-over-year basis, increasing 0.6% from the same period a year
Delta Reports Strong March Quarter; Airline Stocks are Too Risky for Our Taste
April 10, 2024
Image Source: Colin Brown By Brian Nelson, CFA On April 10, Delta Air Lines (DAL) reported solid results for its quarter ending in March. On an adjusted basis, operating revenue came in at $12.6 billion (up 6%), while adjusted operating income came in at $640 million with an operating margin of 5.1%. Adjusted pre-tax income was $380 million, revealing a pre-tax margin of 3.0%. Adjusted earnings per share came in at $0.45 per share, while the company hauled in adjusted operating cash flow of $2.5 billion. Free cash flow was a robust $1.4 billion, while its adjusted debt to EBITDAR came in at 2.9x, down modestly from the end of 2023. Return on invested capital was 13.8% on a trailing
How Well Do Enterprise-Cash-Flow-Derived Fair Value Estimates Predict Future Stock Prices? — And Thoughts on Behavioral Valuation
April 10, 2024
Please select the image below to download, “How Well Do Enterprise-Cash-Flow-Derived Fair Value Estimates Predict Future Stock Prices? — And Thoughts on Behavioral Valuation” Abstract: This paper attempts to solidify the efficacy of the predictive power of fair value estimates for stocks, as derived by the discounted enterprise cash flow (free cash flow to the firm) process. The piece emphasizes the difference between share prices and estimated fair (intrinsic) values and offers an overview of the discounted enterprise cash flow model, what causes fair value estimates to change, and what drivers may be most important within the context of the discounted enterprise cash flow model. The work examines the importance of both art and science in discounted enterprise cash
